keyword
https://read.qxmd.com/read/32967918/detection-of-postoperative-plasma-circulating-tumour-dna-and-lack-of-cdx2-expression-as-markers-of-recurrence-in-patients-with-localised-colon-cancer
#1
JOURNAL ARTICLE
Noelia Tarazona, Francisco Gimeno-Valiente, Valentina Gambardella, Marisol Huerta, Susana Roselló, Sheila Zuniga, Alexandre Calon, Juan Antonio Carbonell-Asins, Elisa Fontana, Carolina Martinez-Ciarpaglini, Katherine Eason, Pilar Rentero-Garrido, Tania Fleitas, Federica Papaccio, David Moro-Valdezate, Gift Nyamundanda, Josefa Castillo, Alejandro Espí, Anguraj Sadanandam, Desamparados Roda, Andrés Cervantes
BACKGROUND: Colon cancer (CC) is a heterogeneous disease. Novel prognostic factors beyond pathological staging are required to accurately identify patients at higher risk of relapse. Integrating these new biological factors, such as plasma circulating tumour DNA (ctDNA), CDX2 staining, inflammation-associated cytokines and transcriptomic consensus molecular subtypes (CMS) classification, into a multimodal approach may improve our accuracy in determining risk of recurrence. METHODS: One hundred and fifty patients consecutively diagnosed with localised CC were prospectively enrolled in our study...
September 2020: ESMO Open
https://read.qxmd.com/read/31987268/context-matters-consensus-molecular-subtypes-of-colorectal-cancer-as-biomarkers-for-clinical-trials
#2
REVIEW
E Fontana, K Eason, A Cervantes, R Salazar, A Sadanandam
The Colorectal Cancer Subtyping Consortium identified four gene expression consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal), using multiple microarray or RNA-sequencing datasets of primary tumor samples mainly from early stage colon cancer patients. Consequently, rectal tumors and stage IV tumors (possibly reflective of more aggressive disease) were underrepresented, and no chemo- and/or radiotherapy pretreated samples or metastatic lesions were included...
April 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/31396557/heterocellular-gene-signatures-reveal-luminal-a-breast-cancer-heterogeneity-and-differential-therapeutic-responses
#3
JOURNAL ARTICLE
Pawan Poudel, Gift Nyamundanda, Yatish Patil, Maggie Chon U Cheang, Anguraj Sadanandam
Breast cancer is a highly heterogeneous disease. Although differences between intrinsic breast cancer subtypes have been well studied, heterogeneity within each subtype, especially luminal-A cancers, requires further interrogation to personalize disease management. Here, we applied well-characterized and cancer-associated heterocellular signatures representing stem, mesenchymal, stromal, immune, and epithelial cell types to breast cancer. This analysis stratified the luminal-A breast cancer samples into five subtypes with a majority of them enriched for a subtype (stem-like) that has increased stem and stromal cell gene signatures, representing potential luminal progenitor origin...
2019: NPJ Breast Cancer
https://read.qxmd.com/read/30962964/benefit-from-anti-egfrs-in-ras-and-braf-wild-type-metastatic-transverse-colon-cancer-a-clinical-and-molecular-proof-of-concept-study
#4
JOURNAL ARTICLE
Chiara Cremolini, Matteo Benelli, Elisa Fontana, Filippo Pagani, Daniele Rossini, Giovanni Fucà, Adele Busico, Elena Conca, Samantha Di Donato, Fotios Loupakis, Marta Schirripa, Sara Lonardi, Beatrice Borelli, Elena Ongaro, Katherine Eason, Federica Morano, Mariaelena Casagrande, Matteo Fassan, Anguraj Sadanandam, Filippo de Braud, Alfredo Falcone, Filippo Pietrantonio
OBJECTIVE: Primary tumour location is regarded as a reliable surrogate of colorectal cancer biology. Sensitivity to anti-EGFRs (Epidermal Growth Factor Receptor) of metastatic transverse colon cancers (mTCCs) has usually been assumed similar to right-sided tumours; however, evidence about the clinical behaviour of mTCC is limited. Thus, to verify sensitivity of mTCC to anti-EGFRs we conducted the present study. METHODS: Patients with RAS/BRAF wild-type microsatellite stable (MSS) mTCC receiving anti-EGFR monotherapy, or in combination with irinotecan if clearly irinotecan-refractory, were included...
2019: ESMO Open
https://read.qxmd.com/read/30796810/context-matters-consensus-molecular-subtypes-of-colorectal-cancer-as-biomarkers-for-clinical-trials
#5
REVIEW
E Fontana, K Eason, A Cervantes, R Salazar, A Sadanandam
The Colorectal Cancer Subtyping Consortium identified four gene expression consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal), using multiple microarray or RNA-sequencing datasets of primary tumor samples mainly from early stage colon cancer patients. Consequently, rectal tumors and stage IV tumors (possibly reflective of more aggressive disease) were underrepresented, and no chemo- and/or radiotherapy pretreated samples or metastatic lesions were included...
April 1, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/24406433/reconciliation-of-classification-systems-defining-molecular-subtypes-of-colorectal-cancer-interrelationships-and-clinical-implications
#6
COMMENT
Anguraj Sadanandam, Xin Wang, Felipe de Sousa E Melo, Joe W Gray, Louis Vermeulen, Douglas Hanahan, Jan Paul Medema
Recently we published two independent studies describing novel gene expression-based classifications of colorectal cancer (CRC). Notably, each study stratified CRC into a different number of subtypes: one reported 3 subtypes, whereas the second highlighted 5. Given that each ascribed clinical significance, distinctive biology, and therapeutic prognosis to the different subtypes, we sought to reconcile this apparent incongruity in subtype stratification of CRC, and to interrelate the results. To do so, we each evaluated the other's data sets and analytical methods and discovered that the subtypes and their classifiers are, in fact, clearly related to each other; indeed, the 5 subtype outcomes can be coalesced into the same three...
2014: Cell Cycle
https://read.qxmd.com/read/23584089/a-colorectal-cancer-classification-system-that-associates-cellular-phenotype-and-responses-to-therapy
#7
JOURNAL ARTICLE
Anguraj Sadanandam, Costas A Lyssiotis, Krisztian Homicsko, Eric A Collisson, William J Gibb, Stephan Wullschleger, Liliane C Gonzalez Ostos, William A Lannon, Carsten Grotzinger, Maguy Del Rio, Benoit Lhermitte, Adam B Olshen, Bertram Wiedenmann, Lewis C Cantley, Joe W Gray, Douglas Hanahan
Colorectal cancer (CRC) is a major cause of cancer mortality. Whereas some patients respond well to therapy, others do not, and thus more precise, individualized treatment strategies are needed. To that end, we analyzed gene expression profiles from 1,290 CRC tumors using consensus-based unsupervised clustering. The resultant clusters were then associated with therapeutic response data to the epidermal growth factor receptor-targeted drug cetuximab in 80 patients. The results of these studies define six clinically relevant CRC subtypes...
May 2013: Nature Medicine
https://read.qxmd.com/read/20833451/synthesis-and-cytotoxicity-evaluation-of-novel-1-4-disubstituted-1-2-3-triazoles-via-cui-catalysed-1-3-dipolar-cycloaddition
#8
JOURNAL ARTICLE
Jyothi Vantikommu, Sadanandam Palle, Punganuru Surendra Reddy, Vinodkumar Ramanatham, Mukkanti Khagga, Venkateswara Rao Pallapothula
A facile and highly efficient method for the regioselective synthesis of 1,4-disubstituted 1,2,3-triazoles (β-keto 1,2,3-triazoles) in good to excellent yields from in-situ generated β-ketoazides and terminal alkynes through Cu(I) catalyzed 1,3 dipolar cycloaddition is described. This reaction proceeds smoothly either in water or in a 1:1 mixture of water and acetone at room temperature without use of any additive. The synthesized compounds were screened for their cytotoxicity in A549 (Lung Cancer), HT-29 (Colon Cancer), He La (Cervical Cancer) using MTT assay that exhibited significant cytotoxicity at modest doses...
November 2010: European Journal of Medicinal Chemistry
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.